Clinical trials: Adaptive Radiotherapy
Carcinoma, Non-Small-Cell Lung
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Successful treatment of lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in the patient's body and seek to limit any unnecessary radiation to normal parts of the body.
- Trial name
- NCT02492867
- Testing
- Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Michigan Rogel Cancer Center
Sarcoma, Soft Tissue
Evaluation of Adaptive Radiation Therapy in Pre-operative or Exclusive Radiation Therapy for Limb Soft Tissues Sarcomas
Soft tissue sarcomas (STS) is generally treated by surgery, followed or preceded by radiotherapy and chemotherapy. Preoperative irradiation has been shown to be effective in a randomized trial, and is often indicated in locally…
- Trial name
- ADAPTO-SARC (NCT03680430)
- Testing
- Adaptive radiation therapy
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Institut Paoli-Calmettes
Prostate Cancer (Adenocarcinoma)
Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer.
- Trial name
- SPAR (NCT07344844)
- Testing
- Low-dose CT imaging before each SBRT session
- Where
- Reunion
- Volunteers
- 100 people
- Sponsor
- Clinique Sainte Clotilde
Lung Cancer, Oligometastatic Lung Tumor
One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors
Stereotactic body radiotherapy (SBRT) has become a standard of care for medically inoperable or high-risk operable early-stage non-small cell lung cancer (NSCLC) patients.
- Trial name
- ONE STOP (NCT06236516)
- Testing
- One fraction stereotactic body radiotherapy, HyperSight, Ethos
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Head and Neck Carcinoma, Localized Head and Neck Carcinoma
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)
This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor…
- Conditions
- Head and Neck Carcinoma, Localized Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma
- Trial name
- PULS-Pal (NCT06572423)
- Testing
- Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, Computed Tomography
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Liver Cancer, Intrahepatic Cholangiocarcinoma
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
- Conditions
- Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
- Trial name
- NCT07223307
- Testing
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Stanford University
Head and Neck Cancers, Lung and Esophagus Cancers
Adaptive Pet Study
The purpose of this study is to determine the benefit of using positron emission tomography (PET) in addition to the standard (computed tomography) CT to plan radiation therapy for cancer treatment.
- Conditions
- Head and Neck Cancers, Lung and Esophagus Cancers, Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers
- Trial name
- NCT01908504
- Testing
- PET-CT
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Duke University
Melanoma, Metastatic Malignant Neoplasm in the Spine
Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery
This pilot clinical trial studies adaptive staged stereotactic body radiation therapy (SBRT) in treating patients with spinal metastases that cannot be removed by surgery.
- Conditions
- Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma
- Trial name
- NCT02527304
- Testing
- Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer
Implementation of Online Adaptive Radiotherapy for Breast Cancer Patients on Ethos (BREAST-ART)
Postoperative radiotherapy is for the majority of breast cancer patients the standard of care. During postoperative radiotherapy, unexpected dosimetric deviations can occur due to breast contour changes resulting from resorption…
- Trial name
- BREAST-ART (NCT05727553)
- Testing
- Online adaptive radiotherapy
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Amsterdam UMC, location VUmc
Cancer
Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)
This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes.
- Trial name
- MRL1 (NCT04135794)
- Where
- Canada
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Microsatellite Stable Metastatic Colorectal Cancer
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
To improve the survival in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) by loco-regional therapy with personalized ultra-fractionated radiation plus immunotherpy.
- Trial name
- iPULSAR-CRC (NCT06841159)
- Testing
- Ultra-fractionated radiation therapy, Sintilimab, Standard systemic therapy
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Fudan University
Head and Neck Cancer, Hypoxia
FMISO-based Adaptive Radiotherapy for Head and Neck Cancer
Hypoxia occurs in about 80% of head and neck tumors. Based on experimental and clinical data, hypoxia is a useful parameter for pretherapeutic stratification. These radioresistant regions can be detected with FMISO PET/CT.
- Conditions
- Head and Neck Cancer, Hypoxia, FMISO, Dose Escalation
- Trial name
- FARHEAD (NCT05348486)
- Testing
- Dose escalation
- Where
- 3 sites in Czechia
- Volunteers
- 120 people
- Sponsor
- University Hospital Olomouc
High-grade Glioma
Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.
- Trial name
- NCT06201351
- Testing
- adaptive radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy
- Trial name
- HCC-PULSAR (NCT07884877)
- Testing
- PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Samsung Medical Center
Diffuse Glioma, Glioblastoma
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics.
- Conditions
- Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy, Artificial Intelligence
- Trial name
- GLADIATOR (NCT06492486)
- Testing
- Adaptive radiotherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Centre
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
- Trial name
- NCT06984562
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Squamous Cell Carcinoma
A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer
Treatment adaptation to biological and anatomical changes occurring during treatment can increase the chance of cure at minimized radiation-induced toxicity in head and neck cancer patients.
- Trial name
- NCT01208883
- Testing
- repetitive per-treatment [18F]FDG-PET for treatment adaptation
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Ghent
Salivary Gland Squamous Cell Carcinoma, Stage II Salivary Gland Cancer
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Salivary Gland Squamous Cell Carcinoma, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01283178
- Testing
- intensity-modulated radiation therapy, cisplatin, image-guided adaptive radiation therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc